Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P347 | DOI: 10.1530/endoabs.56.P347

1Department of Nutrition-Related Disease Prevention, School of Public Health in Bytom, Medical University of Silesia, Katowice, Bytom, Poland; 23rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Disease, Zabrze, Poland; 3Department of Laboratory Diagnostics, Mazovian Specialist Hospital in Radom, Radom, Poland; 4Department of Endocrinology, Piekary Medical Center, St. Luke’s Local Hospital in Piekary Ślęskie, Piekary Ślęskie, Poland.


Visfatin (pre-B cell colonyenhancing factor) is a adipocytokine playing an important role in glucose homeostasis. High concentrations of visfatin are observed in obese people. Previous studies suggest that estimation of visfatin concentration could be a promising tool for predicting obesity or its metabolic consequences. The aim of the study was to evaluate the correlation between visfatin concentration, selected anthropometric parameters (BMI, WHR, BAI, VAI index) and biochemical parameters (glucose metabolism parameters). 39 patients without carbohydrate metabolism disorders, diagnosed at endocrinology department because of other reasons were included to the study. The exclusion criteria were any glucose metabolism disorders (diabetes mellitus, insulin resistance, glucose intolerance, fasting glucose impairment) or medications influence glucose concentration and metabolism (glucocorticosteroids, hypoglycaemic drugs, etc.). The data were statistically analyzed by STATISTICA. α=0.05. The median age was 33 years (26–38 years). 69% patients with normal weight (n=27), 21% patients overweight (n=8) and 10% obese (n=4). The median BMI was 23.7 kg/m2 (21.1–26.5 kg/m2); WHR 0.8 (0.75-0.85); BAI 29% (25-32%); VAI 0.87 (0.61–1.29). The median serum visfatin was 0.7 ng/ml (0.4–5.6 ng/ml); fasting insulin 6.7 μU/ml (5.5–9.1 μU/ml); fasting glucose 88 mg/dl (84–93 mg/dl). There were no correlation observed among differences in visfatin concentration (0.7 vs 0.8 vs 0.9, P=0.8) was found between patients of examined groups (respectively patients with normal weight, overweight and obesity) as well as no correlation between visfatin concentration in relation to fasting glucose (R=−0.1, P=0.5564); fasting insulin (R=−0.09, P=0.5662) was observed. Moreover, not significant correlation of BMI and visfatin levels (R=0.06, P=0.7192), WHR index and visfatin levels (R=0.11, P=0.5071), BAI index and visfatin levels (R=0.01, P=0.9571) as well as VAI index and visfatin (R=−0.09; P=0.5913) were observed. Visfatin concentration in healthy individual does not correlate with anthropometric parameters and glucose parameters.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.